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Abstract
Objective: This study was designed to investigate the effect of hypertonic fluid administration on inflammatory
mediator gene expression in patients with septic shock.
Design and setting: Prospective, randomized, controlled, double-blind clinical study in a 15-bed mixed intensive
care unit in a tertiary referral teaching hospital.
Interventions: Twenty-four patients, who met standard criteria for septic shock, were randomized to receive a
bolus of hypertonic fluid (HT, 250 ml 6% HES/7.2% NaCl) or isotonic fluid (IT, 500 ml 6% HES/0.9% NaCl)
administered over 15 minutes. Randomization and study fluid administration was within 24 hours of ICU admission
for all patients. This trial is registered with ANZCTR.org.au as ACTRN12607000259448.
Results: Blood samples were taken immediately before and 4, 8, 12, and 24 hours after fluid administration. Real-
time reverse transcriptase polymerase chain reaction (RT rtPCR) was used to quantify mRNA expression of different
inflammatory mediators in peripheral leukocytes. In the HT group, compared with the IT group, levels of gene
expression of MMP9 and L-selectin were significantly suppressed (p = 0.0002 and p = 0.007, respectively), and
CD11b gene expression tended to be elevated (p = NS). No differences were found in the other mediators
examined.
Conclusions: In septic shock patients, hypertonic fluid administration compared with isotonic fluid may modulate
expression of genes that are implicated in leukocyte-endothelial interaction and capillary leakage.
The study was performed at the Intensive Care Department, Waikato Hospital, and at the Molecular Genetics
Laboratory, University of Waikato, Hamilton, New Zealand.
Trial registration: Australia and New Zealand Clinical Trials Register (ANZCTR): ACTRN12607000259448
Small-volume hypertonic fluid resuscitation has been
investigated extensively, especially in hemorrhagic shock
[1]. The immediate effects include intravascular volume
expansion, restoration of cardiac output and blood pres-
sure, and possibly improvement of regional and microcir-
culatory blood flow. Hypertonic resuscitation also exerts
immunologic and anti-inflammatory effects, which may
be of potential benefit in the early resuscitation and
management of septic shock [2]. Different conventional
hemodynamic optimization strategies in septic patients
result in distinct biomarker patterns [3]. In experimental
human endotoxemia, prehydration shifts the cytokine pat-
tern toward a more anti-inflammatory state and results in
less clinical sepsis symptoms, suggesting an association
between the inflammatory response and the hydration or
resuscitation status of septic patients [4]. In addition, but
mainly based on preclinical studies, volume resuscitation
with hypertonic fluids may exert intrinsic beneficial effects
by modulating the inflammatory response and apoptosis
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any medium, provided the original work is properly cited.in trauma and sepsis; these effects however have not yet
been convincingly shown in clinical studies [5,6]. In
healthy volunteers, hypertonic fluid administration results
in attenuation of neutrophil cytotoxicity and inhibition of
the interaction between neutrophils, platelets, and
endothelium [7]. Hypertonic saline alters neutrophil cell
shape, resulting in cytoskeleton remodelling, which has
implications for signal transduction and the cytotoxic
response. The anti-inflammatory effects on neutrophils,
oxidative burst, and cytokine release are mediated through
the signalling molecule mitogen-activated protein kinase
(MAPK) p38 and suggest the existence of an osmolarity
sensing system in immune cells of humans [8,9].
The immune response during sepsis is complex and
involves a network of control elements that includes
pathogen-associated molecular patterns, cell adhesion
molecules, pro- and anti-inflammatory mediators released
by activated macrophages, and complement activation.
Plasma levels of inflammatory mediators in sepsis reflect
the overflow of these mediators into the bloodstream and
may give limited insight into the actual activation of the
leucocytes and the innate immune system [10]. In a pre-
vious study, we have described the use of real-time reverse
transcriptase polymerase chain reaction (RT rtPCR) to
quantify inflammatory mediator expression in circulating
leukocytes of septic patients [11].
This study was designed to quantify the changes in
inflammatory mediator gene expression in circulating
leukocytes, obtained from septic shock patients who
were randomly assigned to receive a bolus of hypertonic
or isotonic fluid.
Methods
Following approval by the Northern Y Regional Ethics
Committee (NTY/06/08/070), we conducted a single-cen-
ter, double-blind prospective, randomized, controlled
s t u d yi nt h eI n t e n s i v eC a r eU n i to fat e r t i a r yr e f e r r a l
teaching hospital. Informed consent was obtained from
patients or their nearest relative. This study is part of a
trial that investigated the cardiovascular effects and the
effects on gastric and sublingual microcirculation of
hypertonic and isotonic resuscitation, which will be pub-
lished separately. The trial is registered with ANZCTR.org.
au as ACTRN12607000259448.
Study protocol
Consecutive adult patients with septic shock were
screened for inclusion in the study. Septic shock was
defined according to standardized criteria [12]. Patients
were randomized to receive intravenous administration of
250 ml of NaCl 7.2%/6% hydroxyethylstarch (hypertonic
group, HT) or 500 ml of 6% HES (isotonic group, IT) over
15 minutes. Hemodynamic measurements, echocardiogra-
phy, tonometry, and SDF imaging of the sublingual
microcirculatory blood flow will be described in a separate
paper. Blood samples were taken from the arterial catheter
at baseline and after 4, 8, 12, and 24 hours after fluid infu-
sion for further analyses.
Laboratory methods
Real-time reverse transcriptase polymerase chain reaction
(RT rtPCR) was used to quantify mRNA expression of
different sepsis mediators in peripheral leukocytes. Based
on their importance in the immune response and pathol-
ogy of sepsis, we chose ten representative genes from a
variety of different groups of sepsis mediators: inflamma-
tory cytokine interleukin-6 (IL-6), anti-inflammatory
cytokine interleukin-10 (IL-10), chemokine interleukin-8
(IL-8), intercellular adhesion molecule-1 (ICAM-1),
monocyte chemoattractive protein-1 (MCP-1), tissue fac-
tor (TF), integrin cluster of differentiation molecule
CD11b, L-selectin, and matrix metalloproteinase-9
(MMP9). To standardize and normalize the amount of
biological material between samples, a suitable house-
keeper gene (b2 microglobulin, B2M) was chosen [13,14].
Table 1 shows the abbreviation, major activity, and the
source of expression of the investigated mRNA tran-
scripts. A housekeeper gene was used to correct for the
absolute amounts of total mRNA variations between dif-
ferent samples. All primers (Sigma, Australia) were opti-
mized for use by amplification of cDNA using reverse
transcriptase PCR and the resulting amplicons sequenced
for confirmation. To quantify the level of hypertonicity
that was achieved, plasma sodium levels [Na
+] were mea-
sured every 30 min using a point-of-care blood gas analy-
zer (ABL 800 Flex, Radiometer, Copenhagen). To
c o m p a r et h em a g n i t u d eo fp l a s m av o l u m ee x p a n s i o n ,
dilution of hemoglobin (Hb) concentration was assessed
1 hour after the fluid administration.
Laboratory protocol
One milliliter of blood was added to 4 ml of 5 M guani-
dine thiocyanate (GITC) solution to preserve the RNA.
Total cellular RNA was isolated from the cell samples
using the following method: 0.5 ml 2 M sodium acetate
(pH 4), and 2.0 ml of 100% ethanol were added to the
GITC-lysed blood and the sample mixed and allowed to
stand in an ice bucket for 10 min before being centrifuged
for 15 min at 15,000 (g) at 4°C. The supernatant was care-
fully decanted so as not to disturb the pellet, which was
resuspended in 0.5 ml of GITC solution and then mixed.
When the pellet was dissolved, 50 μl of 2 M sodium acet-
ate was added followed by 0.5 ml of water-saturated phe-
nol. The solution was placed on ice for 10 min and then
200 μl of chloroform added and the tube vortexed before
being centrifuged at 16,000 g for 10 min. The top layer
was removed to new tube and an equal volume of 100%
Analar Isopropanol added and mixed by invertion,
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min to precipitate the total RNA. The tube was recentri-
fuged at 16,000 g for 10 min, the supernatant removed
and the pellet resuspended in 1 ml of 70% ethanol, and
then centrifuged at 16,000 (rpm or g) for 5 min. The etha-
nol was removed and the pellet briefly air dried. The pellet
was resuspended in 18 μl of Tris/Mn RNA buffer and 2 μl
of Promega DNase solution was added and the sample
incubated, shaking at 37°C for 30 min to digest any con-
taminating DNA. A total of 2 μlo fS t o ps o l u t i o nw a s
added, heated, and shaken at 65°C for 10 minutes, with
the samples then put on ice. Quality and quantity of RNA
checked on a Nanodrop instrument by measuring absor-
bance at 260-, 280-, and 203-nm wavelength.
Ac D N Ac o p yo ft o t a lR N Aw a sp r e p a r e du s i n gt h e
SuperScript III reverse transcriptase first strand cDNA
synthesis kit (Invitrogen, Carlsbad, CA) according to the
manufacturers instructions, using oligo(dT)15 (Roche
Molecular Systems, Pleasanton, CA) to prime the reac-
tions. Briefly, reverse transcription reactions were per-
formed using a PTC200 DNA engine (BioRad, Hercules,
USA) in tubes using 1.0 to 1.5 μgR N A ,1μLo f5 0μM
Oligo dT (Roche, Auckland, NZ), and sterile MQ water to
achieve the desired volume. The tube was then heated to
70°C for 5 min to destroy any RNA secondary structures.
The tubes were cooled on ice before the reverse transcrip-
tase components were added. The enzyme mix for each
sample contained 2.5 μL of sterile MQ water, 4 μL5 Xf i r s t
strand buffer, 1 μL of 0.1 M DTT, 1 μLo fd N T Pm i x
(10 mM), to which was added 0.5 μLo fS u p e r S c r i p t I I I
(Invitrogen). This was added to the 0.2-mL tubes contain-
ing the RNA and Oligo dT mixture using an electronic
dispenser, mixed, then spun down (5 k rpm for 20 sec-
onds) and left at 25°C for 5 minutes before incubating at
50°C for 1 hour. The reaction was then halted by heating
at 70°C for 15 minutes.
A check of cDNA production was performed by amplifi-
cation of the housekeeping gene b2 M using 0.5 μL cDNA
samples with negative controls. The cycle time and tem-
perature settings were initially 95°C, 2 minutes; then 40
repeating cycles of 94°C, 20 seconds; 55°C, 20 seconds, 68°
C, 30 seconds; before a final step of 68°C for 5 minutes.
The cDNA samples were stored at -70°C until used in
reverse transcriptase polymerase chain reaction (rtPCR).
Real-time rtPCR quantification
PCR products were labelled with SYBR
® 82 (Invitrogen).
RT rtPCR was performed in 100-μL thin-walled tubes
(Corbett Research) and monitored in a Rotor-Gene™
6000 (Corbett Research). Each 20-μL reaction mixture
contained real-time PCR Mastermix (10× Thermostart
®
Reaction Buffer (AB Ltd.), 1/20,000 dilution of SYBR
®
82, 5 mM MgCl2 pH 8.5, 0.5 U of ABGene Thermo-
start
® DNA polymerase (AB Ltd.), and 5 pmol of for-
ward and reverse primers), and approximately 1 μLo f
cDNA.
Following an initial denaturation step at 95°C for 15
minutes, 40 cycles were performed using 94°C for 20
seconds, annealing at 55°C for 20 seconds, extension at
68°C for 30 seconds, and fluorescence acquisition at 80°
C for 10 seconds using the yellow channel (excitation at
530 nm, detection at 555 nm).
Following amplification in each run, a dissociation melt
curve was determined. PCR products were heated from
Table 1 Sources and biological effect of investigated inflammatory mediators
Inflammatory mediator Abbreviation Major cell sources Major activity
Interleukin 6 IL-6 T cells, macrophages Mediator of fever and acute phase response. Has both pro- and
anti-inflammatory properties
Interleukin 8 IL-8 Macrophages, epithelium,
endothelium
Mediator inflammatory response. Chemotactic mainly for
neutrophils
Interleukin 10 IL-10 Monocytes, lymphocytes Anti-inflammatory, inhibits synthesis various pro-inflammatory
cytokines
Intercellular adhesion
molecule 1
ICAM-1 Leucocytes, endothelium Facilitates leucocyte endothelial transmigration, signal transduction
pro-inflammatory pathways
Monocyte
chemoattractant protein
1
MCP-1 Monocytes, endothelium, smooth
muscle cells
Chemotactic mainly for monocytes
Tissue factor TF Subendothelial tissue, platelets,
leucocytes
Initiation coagulation cascade, intracellular signalling (angiogenesis,
apoptosis)
Cluster of differentiation
molecule 11b
CD11b Monocytes, neutrophils,
macrophages, natural killer cells
Regulates leucocyte adhesion and migration, implicated in
phagocytosis and cell mediated cytotoxicity
L-selectin L-selectin Leucocytes Adhesion and homing receptor for leucocytes to enter secondary
lymphoid tissues
Matrix metalloproteinase
9
MMP9 Macrophages, neutrophils,
endothelium
Breakdown extracellular matrix, invasion of inflammatory cells
b2 microglobulin Housekeeping gene
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curves showed a single peak consistent with the presence
of a single amplicon. Each reaction was run in duplicate,
and the Ct values (Roto-Gene software, version 1.7) and
PCR efficiencies were aver a g e d[ 1 5 ] .T h em e a nC ta n d
PCR efficiency values were used to estimate the initial
copy number (ICN) of mRNA transcripts of each particu-
lar gene, including the house-keeping gene (B2M) [16]. To
correct for different concentrations of mRNA, 1 μgo f
total RNA was used to make cDNA and then the ratio of
the Housekeeper gene to the gene of interest was used.
Because the housekeeper gene is not affected by the treat-
ment, the Ct and the efficiency of amplification could be
used to adjust for significant difference in the starting con-
centration of mRNAs. Specimens in which the RNA yield,
quality, or amplification efficiency were compromised
were rejected for analysis.
Data analysis
The level of gene expression was quantified using the
initial copy number. We did a logarithmic transformation
on this number to achieve a normal distribution of the
data and hence to allow the use of repeated measures
analysis of variance (ANOVA). “Treatment-group” was
the between-subject variable, and “time” was the within-
subject variable. The “time×treatment-group” interaction
term was the indication of the evolution of different
responses between the two treatment groups. We used
the Tukey-Kramer Multiple-Comparison test for post-
hoc comparisons at different times. The Student test was
used to compare parameters with a normal distribution,
and the effects on nonnormally distributed parameters
were compared by using the Mann-Whitney test and the
Wilcoxon signed-rank test for paired measurements.
Bonferroni correction was used to adjust for multiple
(n = 7) comparisons. Using this correction, p < 0.0071
was considered to be significant. All statistical calcula-
tions were performed using NCSS 2007 (version 07.1.13,
NCCS, Kaysville, UT).
Results
Baseline characteristics are shown in Table 2. The treat-
ment groups had similar severity of disease, as expressed
by APACHE II and SOFA scores. All patients required
vasoactive drugs for hemodynamic support as required
for the diagnosis of septic shock. None of the patients
received immunosuppressive agents, such as steroids
before or during the study. No differences in baseline
counts of white blood cells (WBC) and polymorphonuc-
lear cells (PMN) were present (Table 2).
Gene expression at baseline
The expression at baseline of all measured mediators was
comparable between the two groups (Figure 1). The genes
IL-6 and TF were insufficiently expressed to use for further
data analysis. Patients with abdominal sepsis had signifi-
cantly more variability in the baseline gene expression
compared with the other sepsis patients (SD 4.1 ± 0.8 vs.
2.8 ± 0.8, p = 0.03). The expression of MMP9 in patients
with abdominal sepsis tended to be higher compared with
patients with pulmonary or other sepsis (16.5 ± 3.5 vs. 13.9
± 2.6 and 15.2 ± 3.7), but this difference did not reach sta-
tistical significance (p =0 . 2 1a n dp = 0.57, respectively).
Treatment effects
In the HT group, [Na+] increased from 135 ± 5 mmol/l at
baseline to 143 ± 7 mmol/l after 30 min (p < 0.0001) and
decreased to 140 mmol/l after 2 hours and did not change
after that. This increase corresponds with a plasma osmol-
ality of approximately 300 mOsm/kg. No significant
change in [Na+] was found in the IT group. The Hb con-
centration before the fluid infusion was not statistically
different between the groups (HT 108 ± 15 g/l, IT 96 ±
17g/l; p = 0.07). In both groups, fluid administration sig-
nificantly decreased Hb after 1 hour (HT 99 ± 15 g/l, p <
0.00001; IT 84 ± 15, p < 0.00001). The magnitude of
hemodilution as assessed by the difference in Hb after
1 hour was similar between groups (HT 9.0 ± 2.2 g/l, IT
11.6 ± 4.5 g/l; p = 0.09). The WBC count following study
fluid administration did not change significantly from
baseline (IT 11 [8-17] × 10
9/l, p = 0.54; HT 17 [11-25] ×
10
9/l, p = 0.52) and was not different between the treat-
ment groups (p = 0.15). The PMN count after treatment
also was not different from baseline (IT 10 [7-16] × 10
9/l,
p = 0.44; HT 15 [8-22] × 10
9/l, p = 0.98) or between
groups (p = 0.28).
The expression of the investigated genes over time in
both treatment groups is shown in Figure 1. MMP9
Table 2 Baseline characteristics
Variables IT group (n = 12) HT group (n = 12) P value
Age (yr) 61 ± 13 56 ± 16 0.45
Men 6 (50%) 7 (58%) 0.68
APACHE II 23.5 ± 7.4 24.4 ± 6.7 0.75
SOFA 8.9 ± 2.5 9.8 ± 3.4 0.5
WBC (×10
9/l) 10.7 [7.4-14.5] 14.9 [6.7-35.6] 0.3
PMN (×10
9/l) 9.7 [6.4-12.9] 13.1 [9.9-28.3] 0.28
Source of sepsis
Abdominal (n = 10) 5 5
Pneumonia (n = 8) 5 3
Soft tissue (n = 3) 1 2
Other (n = 3) 1 2
APACHE, Acute Physiology and Chronic Health Evaluation; SOFA, Sequential
Organ Failure Assessment; WBC, white blood cell count; PMN,
polymorphonuclear leucocytes.
Data are presented as mean ± SD, as numbers (%) or as median [interquartile
range].
van Haren et al. Annals of Intensive Care 2011, 1:44
http://www.annalsofintensivecare.com/content/1/1/44
Page 4 of 8showed a significant effect over time (ANOVA, p =
0.001, expression at 24 hr different from expression at 8
hr and 12 hr (post-hoc test)) and the interaction term
(ANOVA, p = 0.0002). This indicates that the MMP9
expression at 24 hr decreased in the HT group, whereas
in the IT group the MMP9 expression was still elevated
(Figure 1A). L-selectin expression also was more sup-
pressed after more than 4 hr in the HT group compared
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Figure 1 Changes in inflammatory mediator genes over time for the two treatment groups. Hypertonic group, solid line; isotonic group,
dotted line. Data are expressed as mean (SD) of the logarithm of the initial copy number.
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Page 5 of 8with the IT group (ANOVA, p = 0.007; Figure 1B).
CD11b showed a nonsignificant increase in expression
over the first 8 hr (time ANOVA, p = 0.04), an effect
that was more pronounced in the HT compared with
the IT group (ANOVA, p = 0.02). However, after 12 hr,
the levels returned to time = 0 levels in the IT group,
b u tr e m a i n e de l e v a t e di nt h eH Tg r o u p( F i g u r e1 C ) .
The other mediators ICAM, IL8, IL-10, and MCP-1 did
not show any significant changes over time or between
treatment groups (Figure 1).
Discussion
In this study, we examined the effects of hypertonic ver-
sus isotonic fluid administration on circulating leukocyte
expression of important sepsis mediators in septic shock
patients. To our knowledge, this has not been studied
before in this group of patients.
Hypertonic fluid administration resulted in a different
gene expression pattern compared with isotonic fluid. In
the HT group, the expression of MMP9 and L-selectin
was suppressed compared with the IT group. CD11b
tended to remain elevated after 12 hr in the HT group
while returning to baseline in the IT group.
Our study has several limitations. Septic shock patients
are not a homogenous population, and the expression of
inflammatory mediators is highly variable and not only
dependent on the source of sepsis but also on the genetic
make up of the host, which defines the immune response
[17]. We did not directly measure inflammatory mediator
peptide levels in the peripheral blood, which is the more
common way to study the immune response to sepsis.
The levels and dynamics of these mediators correlate with
outcome [18-20]. One of the main problems when mea-
suring inflammatory mediator peptide levels in the periph-
eral blood is that only the endocrine overflow is measured,
not the local autocrine and paracrine receptor binding
effects [10,11]. On the other hand, measuring expression
of the inflammatory mediator genes may not reflect the
functional activity of the end-protein, because this also
depends on translation and various posttranslational mod-
ifications that determine whether the protein becomes
active. Currently there are no methods to measure func-
tional protein activity reliably. In addition, inflammatory
gene activation tends to be a slow process and can take
many hours depending on the gene measured. This is in
contrast to the immediate and short-term changes
observed in inflammatory mediator peptide levels in per-
ipheral blood and could account for the time course of
changes found in our study. In addition, our methodology
does not allow us to distinguish between direct effects and
indirect effects, e.g., downstream in a cascade of events, or
induced by a change in the level of inhibition. Also, our
measurements were limited to circulating leucocytes, and
thus our study does not provide information on gene
expression in adherent or migrated neutrophils. Even cell
separation procedures would not be able to detect inflam-
matory mediator expression in cells within the tissues.
Furthermore, the level of hypertonicity that was achieved
in the HT group may not have been optimal to signifi-
cantly influence immune function. It has been proposed
that the level of hypertonicity should probably exceed 330
mOsm/kg to benefit patients in terms of immune function
[21]. Finally, hydroxyethyl starch solutions have been
shown to have an effect on markers of inflammation and
endothelial injury [22]. The two patient groups in our
study received a different amount of hydroxyethyl starch,
which theoretically could exert a different effect on the
gene expression of inflammatory mediators, although this
effect may not be dose-dependent.
MMP9 is released from granules of neutrophils and
induces capillary leakage by degrading endothelial mem-
branes. High plasma levels of this inflammatory marker
as well as high mRNA expression in septic patients have
been reported previously [11,23,24]. Both plasma MMP9
concentrations and monocyte MMP9 mRNA levels were
significantly higher in nonsurvivors than in survivors of
septic shock [24]. Hypertonic fluid administration has
been shown to reduce capillary leakage and improve
capillary blood flow in several studies [6,25]. This effect
has been attributed mainly to the direct osmotic effects
on endothelial cell swelling and luminal narrowing
[26,27]. Our finding of suppression of MMP9 could be
used to generate an alternative hypothesis by which
hypertonic fluids may reduce capillary leakage and edema
formation, which should be investigated further.
Although we did not specifically investigate the degree of
capillary leakage in our study, we did find that patients
treated with hypertonic fluid needed significantly less
fluid in the following 24 hours compared with patients in
the IT arm (HT 2.8 ± 1.5 liter/24 hours vs. IT 4.1 ± 1.6
liter/24 hours, p = 0.046).
L-selectin is a transmembrane glycoprotein expressed on
leucocytes, involved in rolling and adhesion of leucocytes
along vessel walls adjacent to the site of injury. The bind-
ing through L-selectin is dependent on sufficient shear
stress above a critical threshold, to promote and maintain
rolling interactions [28]. In our study, expression of
L-selectin was depressed in the HT group. This finding is
consistent with previous findings and suggests that hyper-
tonic fluid modulates the immune response by preventing
neutrophil adhesion to the endothelium [2,29-31]. In sev-
eral animal models of shock, intravital microscopy was
used to visualize neutrophil rolling and adhesion to the
endothelium in a real-time fashion. Hypertonic resuscita-
tion has been shown to decrease neutrophil rolling and
adherence [6,25].
The mediator CD11b is member of the integrin family,
which is responsible for adhesion of leucocytes to
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tively and kept largely in an inactive state to undergo in
situ activation upon leukocyte-endothelial contact by both
biochemical and mechanical signals. This activation pro-
cess takes place within fractions of seconds by in situ sig-
nals transduced to the rolling leukocyte as it encounters
specialised endothelial-displayed chemoattractants [32,33].
Our finding of a possible trend toward elevated gene
expression of CD11b after 12 hours in the HT group com-
pared with control is not easy to interpret. Rizoli and cow-
orkers showed in animal models of hemorrhagic shock
that hypertonic fluid prevents LPS-stimulated expression
and activation of CD11b in the lung [34,35]. In a rando-
mized, controlled study by the same group in patients with
traumatic hemorrhagic shock, hypertonic fluid abolished
shock-induced CD11b up-regulation [36]. There are
important differences between these studies and ours that
could account for the different findings. Hemorrhagic
shock and septic shock are distinctly different disease pro-
cesses with important differences in immune response.
Furthermore, timing of the intervention may be important
[37]. In the animal experiments described, hypertonic fluid
was given before the LPS challenge, which is obviously
unachievable in patients already in septic shock.
We were unable to measure sufficient expression of
the inflammatory genes for IL-6 and TF to include them
in our analysis. During sepsis, the vast majority of circu-
lating leucocytes are neutrophils, with hardly any circu-
lating monocytes, because these are known to migrate
out of the circulation. This means that our measure-
ments essentially targeted gene expression in neutro-
phils, whereas IL-6 is mainly expressed in monocytes
and TF in (sub)endothelium. In other words, despite
high plasma protein levels of IL-6 in sepsis, the actual
gene expression in circulating leucocytes is expected to
be very low. Another or contributory explanation could
be that high blood levels of inflammatory peptides may
result in homeostatic suppression of the associated
genes.
Similar to our previous study [11], there was a trend
toward increased expression of MMP9 in patients with
abdominal sepsis compared with other forms of sepsis,
although in the present study this difference did not reach
statistical significance. This observation reiterates that the
inflammatory response in sepsis is heterogeneous depend-
ing on the source and the infecting organism.
In conclusion, we have shown that in septic shock
patients, hypertonic fluid, compared with isotonic fluid,
may modulate expression of several, but not all, measured
genes that are implicated in neutrophil-endothelial inter-
action and capillary leakage. To our knowledge, this is the
first study to report the effects of hypertonic resuscitation
on inflammatory gene expression in septic shock patients.
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